Wedbush Cuts Earnings Estimates for Viridian Therapeutics

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Research analysts at Wedbush reduced their Q3 2025 earnings per share estimates for Viridian Therapeutics in a report released on Monday, October 27th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.85) per share for the quarter, down from their previous forecast of ($0.13). The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. Wedbush also issued estimates for Viridian Therapeutics’ Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($2.84) EPS, Q1 2026 earnings at ($0.79) EPS, Q2 2026 earnings at ($0.90) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($3.46) EPS, FY2027 earnings at ($2.18) EPS and FY2028 earnings at $3.78 EPS.

Other analysts have also recently issued research reports about the company. Needham & Company LLC cut their price objective on Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. Jefferies Financial Group began coverage on Viridian Therapeutics in a research note on Monday, August 25th. They set a “buy” rating and a $44.00 price objective on the stock. Royal Bank Of Canada cut their price objective on Viridian Therapeutics from $45.00 to $41.00 and set an “outperform” rating on the stock in a research note on Thursday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company dropped their price target on Viridian Therapeutics from $27.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 7th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $35.38.

Viridian Therapeutics Trading Up 2.8%

Shares of NASDAQ VRDN opened at $23.66 on Thursday. The stock’s 50 day moving average price is $20.57 and its two-hundred day moving average price is $17.02. Viridian Therapeutics has a 52-week low of $9.90 and a 52-week high of $27.20. The stock has a market capitalization of $1.93 billion, a P/E ratio of -6.18 and a beta of 0.49. The company has a quick ratio of 11.01, a current ratio of 11.01 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.00). Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%.The firm had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.05 million. During the same quarter in the prior year, the firm posted ($0.81) earnings per share. Viridian Therapeutics’s revenue for the quarter was up 4.2% compared to the same quarter last year.

Insider Transactions at Viridian Therapeutics

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc acquired 454,545 shares of the firm’s stock in a transaction that occurred on Thursday, October 23rd. The stock was acquired at an average cost of $22.00 per share, with a total value of $9,999,990.00. Following the acquisition, the director directly owned 3,914,458 shares of the company’s stock, valued at $86,118,076. This represents a 13.14% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.58% of the stock is owned by company insiders.

Hedge Funds Weigh In On Viridian Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Commodore Capital LP boosted its stake in Viridian Therapeutics by 35.4% during the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock valued at $68,152,000 after purchasing an additional 1,275,000 shares in the last quarter. Rice Hall James & Associates LLC boosted its stake in Viridian Therapeutics by 65.2% during the 3rd quarter. Rice Hall James & Associates LLC now owns 851,663 shares of the company’s stock valued at $18,379,000 after purchasing an additional 336,040 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Viridian Therapeutics by 33.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock valued at $16,595,000 after purchasing an additional 310,998 shares in the last quarter. HighVista Strategies LLC boosted its stake in Viridian Therapeutics by 168.4% during the 2nd quarter. HighVista Strategies LLC now owns 484,559 shares of the company’s stock valued at $6,774,000 after purchasing an additional 304,008 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP boosted its stake in Viridian Therapeutics by 15.1% during the 1st quarter. Paradigm Biocapital Advisors LP now owns 2,095,079 shares of the company’s stock valued at $28,242,000 after purchasing an additional 275,000 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.